CN113633626B - NMN capsule coating and NMN capsule preparation method and application - Google Patents

NMN capsule coating and NMN capsule preparation method and application Download PDF

Info

Publication number
CN113633626B
CN113633626B CN202110856282.5A CN202110856282A CN113633626B CN 113633626 B CN113633626 B CN 113633626B CN 202110856282 A CN202110856282 A CN 202110856282A CN 113633626 B CN113633626 B CN 113633626B
Authority
CN
China
Prior art keywords
parts
nmn
coating
weight
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110856282.5A
Other languages
Chinese (zh)
Other versions
CN113633626A (en
Inventor
卢健行
李飞
苏艺
马善丽
王芳
赵鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Runde Biotechnology Co Ltd
Original Assignee
Shandong Runde Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Runde Biotechnology Co Ltd filed Critical Shandong Runde Biotechnology Co Ltd
Priority to CN202110856282.5A priority Critical patent/CN113633626B/en
Publication of CN113633626A publication Critical patent/CN113633626A/en
Application granted granted Critical
Publication of CN113633626B publication Critical patent/CN113633626B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a NMN capsule coating, a NMN capsule preparation method and application. The coating comprises: the inner coating comprises the following components in parts by weight: 3-6 parts of shellac, 0.3-1.5 parts of hydroxypropyl methylcellulose, 0.1-1.2 parts of magnesium stearate, 1-4 parts of sorbitol, 0.8-1.2 parts of titanium dioxide and 30-55 parts of ethanol. The outer coating comprises: 6-9 parts of sodium alginate, 0.3-0.8 part of sodium carboxymethylcellulose, 0.4-0.7 part of fatty glyceride, 0.1-0.6 part of magnesium stearate, 0.8-2 parts of polyvinyl acetate, 1-8 parts of glycerol, 0.5-1 part of dimethyl phthalate, 0.5-1.5 parts of bone meal and 30-55 parts of water. The coating provided by the invention can avoid the influence of light and oxygen on NMN, and can ensure that NMN smoothly passes through gastric juice without disintegration and is disintegrated and absorbed after entering the intestinal tract, thereby improving the utilization rate of NMN.

Description

NMN capsule coating and NMN capsule preparation method and application
Technical Field
The invention relates to the technical field of NMN preparation, in particular to a NMN capsule coating, a NMN capsule preparation method and application.
Background
NMN is known as beta-nicotinamide mononucleotide and is a derivative of nicotinic acid. Nicotinic acid is a vitamin necessary for human body, which exists in the form of nicotinamide in the body, and is converted into coenzyme 1(NAD +) in the body, and plays a role in many biological redox reactions, almost all physiological activities are related to coenzyme 1, including energy metabolism, gene stability, nerve conduction, metabolism, and the like. Studies have demonstrated that NAD + levels decrease by 50% every 20 years with age, and that aging will also accelerate with decreasing NAD + levels in vivo, thereby triggering various symptoms of aging in vivo.
NMN in a human body can be effectively supplemented by orally taking the NMN product. However, NMN is unstable in chemical properties, and is easily oxidized and decomposed into other substances after being affected by light and oxygen, and in addition, NMN is also easily decomposed in gastric juice, so that the utilization rate of NMN by oral administration is low, and the actual effect is not great.
Disclosure of Invention
Aiming at the problems, the invention provides the NMN capsule coating, the NMN capsule preparation method and the application, the coating can not only prevent the NMN from being influenced by light and oxygen, but also ensure that the NMN can smoothly pass through gastric juice without disintegration and can be disintegrated and absorbed after entering the intestinal tract, thereby improving the utilization rate of the NMN. In order to achieve the purpose, the invention discloses the following technical scheme:
in a first aspect of the invention, there is disclosed a capsule coating of NMN, the coating comprising an inner coating and an outer coating, wherein: the inner coating comprises the following components in parts by weight: 3-6 parts of shellac, 0.3-1.5 parts of hydroxypropyl methyl cellulose, 0.1-1.2 parts of magnesium stearate, 1-4 parts of sorbitol, 0.8-1.2 parts of titanium dioxide and 30-55 parts of ethanol. The outer coating comprises: 6-9 parts of sodium alginate, 0.3-0.8 part of sodium carboxymethylcellulose, 0.4-0.7 part of fatty glyceride, 0.1-0.6 part of magnesium stearate, 0.8-2 parts of polyvinyl acetate, 1-8 parts of glycerol, 0.5-1 part of dimethyl phthalate, 0.5-1.5 parts of bone meal and 30-55 parts of water.
In a second aspect of the invention, a method for preparing NMN capsules is disclosed, comprising the steps of:
(1) and mixing the components of the inner coating, and uniformly stirring to obtain an inner coating solution for later use.
(2) Mixing the components of the outer coating, and stirring uniformly to obtain an outer coating solution for later use.
(3) And mixing the NMN, the granulating agent and water, uniformly stirring, and then granulating to obtain NMN particles.
(4) Spraying the inner coating liquid on the surface of the NMN particles, and then drying; and spraying the outer coating liquid on the surface of the inner coating, and drying to obtain the NMN capsule with the double-layer coating.
Further, in step (1), the inner coating comprises by weight: 3-6 parts of shellac, 0.3-1.5 parts of hydroxypropyl methylcellulose, 0.3-1.2 parts of magnesium stearate, 1-4 parts of sorbitol, 0.8-1.2 parts of titanium dioxide and 30-55 parts of ethanol.
Further, in the step (2), the outer coating comprises the following components in parts by weight: 6-9 parts of sodium alginate, 0.3-0.8 part of sodium carboxymethylcellulose, 0.4-0.7 part of fatty glyceride, 0.1-0.6 part of magnesium stearate, 0.8-2 parts of polyvinyl acetate, 1-8 parts of glycerol, 0.5-1 part of dimethyl phthalate, 0.5-1.5 parts of bone meal and 30-55 parts of water.
Further, in the step (3), the granulating agent is a mixture of fatty acid monoglyceride and phospholipid in a mass ratio of 1.2-1.5: 1.
Alternatively, the monoglyceride of fatty acids may be any one selected from the group consisting of glycerol monostearate, glycerol monolaurate, glycerol monooleate, and the like.
Optionally, the phospholipid is selected from egg yolk lecithin, soybean phospholipid, sunflower phospholipid, etc.
Further, in the step (3), the mass ratio of the NMN to the granulating agent to the water is 3.5-5: 1.5-2: 4 to 7.5.
In a third aspect of the invention, the NMN capsule coating, NMN capsules use in the fields of medicine, rehabilitation, etc. is disclosed.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention adopts a mode of coating double-layer coats on the NMN particles, which not only can avoid the influence of light and oxygen on the NMN, but also can ensure that the NMN can smoothly pass through gastric juice without disintegration and can be disintegrated and absorbed after entering the intestinal tract, thereby improving the utilization rate of the NMN.
(2) The inner coating adopted by the invention is added with titanium dioxide, wherein the titanium dioxide is used as a light shielding agent, so that NMN decomposition caused by invisible light such as ultraviolet rays in light passing through the coating can be avoided, meanwhile, the inner coating can be gradually dissolved in intestinal tracts, so that NMN is gradually released slowly, a longer drug effect is kept, and meanwhile, the phenomenon that the concentration of NMN is too high to stimulate long islands and easily cause the concentration fluctuation of NMN in blood is avoided.
(3) The outer coating adopted by the invention is added with bone meal which is a brown substance and can effectively block the transmission of visible light, so that the light penetrating into NMN is reduced as much as possible by matching the outer coating with the inner coating. Meanwhile, the outer coating is slowly dissolved by utilizing the time of temporarily storing the capsule in gastric juice and releases bone meal, the bone meal releases a large amount of inorganic salt after being decomposed by the gastric juice to supplement trace elements for human bodies, and simultaneously, the inner layer is exposed, the capsule can directly start to be dissolved after entering the intestinal tract, so that the capsule is desorbed and absorbed in the retention time period in the intestinal tract.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. The invention will now be further illustrated by specific examples.
Example 1
A preparation method of the NMN capsule comprises the following steps:
(1) mixing 5 parts of shellac, 1 part of hydroxypropyl methyl cellulose, 0.5 part of magnesium stearate, 3 parts of sorbitol, 1 part of titanium dioxide and 45 parts of ethanol by weight, and uniformly stirring to obtain an inner coating solution for later use.
(2) Mixing 8 parts by weight of sodium alginate, 0.5 part by weight of sodium carboxymethylcellulose, 0.7 part by weight of fatty glyceride, 0.5 part by weight of magnesium stearate, 1.2 parts by weight of polyvinyl acetate, 4 parts by weight of glycerol, 0.5 part by weight of dimethyl phthalate, 1 part by weight of bone meal and 45 parts by weight of water, and uniformly stirring to obtain an outer-layer coating solution for later use.
(3) NMN, a granulating agent (formed by mixing glycerol monolaurate and soybean lecithin according to the mass ratio of 1.2: 1) and water are mixed according to the weight ratio of 4: 2: 5, stirring uniformly, and then placing in a granulator for granulation to obtain the NMN granules.
(4) Spraying the inner coating liquid on the surface of the NMN particles, and then drying; and spraying the outer coating liquid on the surface of the inner coating, and drying again to obtain the NMN capsule with the double-layer coating.
Example 2
A preparation method of the NMN capsule comprises the following steps:
(1) according to parts by weight, 3 parts of shellac, 0.5 part of hydroxypropyl methyl cellulose, 0.3 part of magnesium stearate, 2 parts of sorbitol, 0.8 part of titanium dioxide and 30 parts of ethanol are mixed and stirred uniformly to obtain inner-layer coating liquid for later use.
(2) Mixing 6 parts by weight of sodium alginate, 0.3 part by weight of sodium carboxymethylcellulose, 0.4 part by weight of fatty glyceride, 0.1 part by weight of magnesium stearate, 0.8 part by weight of polyvinyl acetate, 1 part by weight of glycerol, 0.6 part by weight of dimethyl phthalate, 0.5 part by weight of bone meal and 30 parts by weight of water, and uniformly stirring to obtain an outer-layer coating solution for later use.
(3) NMN, a granulating agent (formed by mixing glycerol monooleate and egg yolk lecithin in a mass ratio of 1.3: 1) and water are mixed according to a ratio of 3.5: 1.5: 4, uniformly stirring, and then placing in a granulator for granulation to obtain the NMN granules.
(4) Spraying the inner coating liquid on the surface of the NMN particles, and then drying; and spraying the outer coating liquid on the surface of the inner coating, and drying again to obtain the NMN capsule with the double-layer coating.
Example 3
A preparation method of the NMN capsule comprises the following steps:
(1) mixing 6 parts of shellac, 1.2 parts of hydroxypropyl methyl cellulose, 1.2 parts of magnesium stearate, 1 part of sorbitol, 0.6 part of titanium dioxide and 45 parts of ethanol by weight, and uniformly stirring to obtain an inner coating solution for later use.
(2) Mixing 9 parts of sodium alginate, 0.5 part of sodium carboxymethylcellulose, 0.5 part of fatty glyceride, 0.6 part of magnesium stearate, 1.2 parts of polyvinyl acetate, 6 parts of glycerol, 1 part of dimethyl phthalate, 1 part of bone meal and 45 parts of water by weight, and uniformly stirring to obtain an outer-layer coating solution for later use.
(3) NMN, a granulating agent (formed by mixing glyceryl monostearate and egg yolk lecithin in a mass ratio of 1.3: 1) and water are mixed according to a ratio of 3.5: 2: 4.5, stirring uniformly, and then placing in a granulator for granulation to obtain the NMN granules.
(4) Spraying the inner coating liquid on the surface of the NMN particles, and then drying; and spraying the outer coating liquid on the surface of the inner coating, and drying again to obtain the NMN capsule with the double-layer coating.
Example 4
A preparation method of the NMN capsule comprises the following steps:
(1) 6 parts of shellac, 1.5 parts of hydroxypropyl methyl cellulose, 0.8 part of magnesium stearate, 4 parts of sorbitol, 1.2 parts of titanium dioxide and 55 parts of ethanol are mixed and stirred uniformly to obtain inner-layer coating liquid for later use.
(2) According to parts by weight, 9 parts of sodium alginate, 0.8 part of sodium carboxymethylcellulose, 0.5 part of fatty glyceride, 0.7 part of magnesium stearate, 2 parts of polyvinyl acetate, 8 parts of glycerol, 0.9 part of dimethyl phthalate, 1.5 parts of bone meal and 55 parts of water are mixed and stirred uniformly to obtain an outer-layer coating solution for later use.
(3) NMN, a granulating agent (formed by mixing glycerin monostearate and sunflower phospholipid according to the mass ratio of 1.5: 1) and water according to the mass ratio of 5: 2: and 7.5, uniformly stirring, and then placing in a granulator for granulation to obtain the NMN granules.
(4) Spraying the inner coating liquid on the surface of the NMN particles, and then drying; and spraying the outer coating liquid on the surface of the inner coating, and drying again to obtain the NMN capsule with the double-layer coating.
Test example 1
A preparation method of the NMN capsule comprises the following steps:
(1) mixing 8 parts by weight of sodium alginate, 0.5 part by weight of sodium carboxymethylcellulose, 0.7 part by weight of fatty glyceride, 0.5 part by weight of magnesium stearate, 1.2 parts by weight of polyvinyl acetate, 4 parts by weight of glycerol, 0.5 part by weight of dimethyl phthalate, 1 part by weight of bone meal and 45 parts by weight of water, and uniformly stirring to obtain an outer-layer coating solution for later use.
(2) NMN, a granulating agent (formed by mixing glycerol monolaurate and soybean lecithin according to the mass ratio of 1.2: 1) and water are mixed according to the weight ratio of 4: 2: 5, stirring uniformly, and then placing in a granulator for granulation to obtain the NMN granules.
(3) Spraying the outer layer coating liquid on the surface of the NMN particles, and then drying; thus obtaining the NMN capsule with the outer coating.
Test example 2
A preparation method of the NMN capsule comprises the following steps:
(1) mixing 5 parts of shellac, 1 part of hydroxypropyl methyl cellulose, 0.5 part of magnesium stearate, 3 parts of sorbitol, 1 part of titanium dioxide and 45 parts of ethanol by weight, and uniformly stirring to obtain an inner coating solution for later use.
(2) NMN, a granulating agent (formed by mixing glycerol monolaurate and soybean lecithin according to the mass ratio of 1.2: 1) and water are mixed according to the weight ratio of 4: 2: 5, stirring uniformly, and then placing in a granulator for granulation to obtain the NMN granules.
(3) And spraying the inner coating liquid on the surface of the NMN particles, and then drying to obtain the NMN capsule with the inner coating.
Test example 3
A preparation method of the NMN capsule comprises the following steps: NMN, a granulating agent (formed by mixing glycerol monolaurate and soybean lecithin according to the mass ratio of 1.2: 1) and water are mixed according to the weight ratio of 4: 2: 5, uniformly stirring, then placing in a granulator for granulation, and drying to obtain the NMN granules.
Performance test
(1) The NMN capsules prepared in example 1 and test examples 1 to 3 were tested for their photostability, specifically: dissolving the NMN capsules in an isopropanol solvent, preparing a solution to be detected with the same NMN concentration, continuously irradiating the solution to be detected for five hours by using an ultraviolet lamp, and then detecting the absorbance of the solution to be detected, wherein the result is shown in Table 1.
TABLE 1
Serial number Example 1 Test example 1 Test example 2 Test example 3
Absorbance decrease value 18.7％ 68.4％ 33.2％ 86.9％
(2) The NMN capsules prepared in example 1 and test examples 1 to 3 were measured for their cumulative release rate in simulated gastric fluid (pH 1.0) and intestinal fluid (pH 6.8) with reference to "chinese pharmacopoeia" 2015 edition, and the results are shown in table 2.
TABLE 2
Figure BDA0003184269170000061
It can be seen that by coating double-layer coats on the NMN particles, the influence of light and oxygen on the NMN can be avoided, and the NMN can smoothly pass through gastric juice without disintegration and can be disintegrated and absorbed after entering the intestinal tract, so that the utilization rate of the NMN can be improved. In addition, the titanium dioxide is used as a light-shading agent, so that the decomposition of NMN caused by that invisible light such as ultraviolet rays in light passes through the coating can be avoided, and the bone powder can effectively block the transmission of the visible light, so that the light which penetrates into the NMN is reduced as much as possible by matching the outer coating with the inner coating.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (6)

1. A capsule coating of NMN, characterized in that the coating comprises an inner coating and an outer coating;
the inner coating comprises the following components in parts by weight: 3-6 parts of shellac, 0.3-1.5 parts of hydroxypropyl methyl cellulose, 0.1-1.2 parts of magnesium stearate, 1-4 parts of sorbitol, 0.8-1.2 parts of titanium dioxide and 30-55 parts of ethanol;
the outer coating comprises, by weight: 6-9 parts of sodium alginate, 0.3-0.8 part of sodium carboxymethylcellulose, 0.4-0.7 part of fatty glyceride, 0.1-0.6 part of magnesium stearate, 0.8-2 parts of polyvinyl acetate, 1-8 parts of glycerol, 0.5-1 part of dimethyl phthalate, 0.5-1.5 parts of bone meal and 30-55 parts of water.
2. The preparation method of the NMN capsule is characterized by comprising the following steps:
(1) mixing the components of the inner coating, and uniformly stirring to obtain an inner coating solution for later use;
(2) mixing the components of the outer coating, and uniformly stirring to obtain an outer coating solution for later use;
(3) mixing NMN, a granulating agent and water, uniformly stirring, and then granulating to obtain NMN particles;
(4) spraying the inner coating liquid on the surface of the NMN particles, and then drying; spraying the outer coating liquid on the surface of the inner coating, and drying to obtain the NMN capsule with the double-layer coating;
in the step (1), the inner coating comprises the following components in parts by weight: 3-6 parts of shellac, 0.3-1.5 parts of hydroxypropyl methyl cellulose, 0.3-1.2 parts of magnesium stearate, 1-4 parts of sorbitol, 0.8-1.2 parts of titanium dioxide and 30-55 parts of ethanol;
in the step (2), the outer coating comprises, by weight: 6-9 parts of sodium alginate, 0.3-0.8 part of sodium carboxymethylcellulose, 0.4-0.7 part of fatty glyceride, 0.1-0.6 part of magnesium stearate, 0.8-2 parts of polyvinyl acetate, 1-8 parts of glycerol, 0.5-1 part of dimethyl phthalate, 0.5-1.5 parts of bone meal and 30-55 parts of water.
3. The method for preparing NMN capsules according to claim 2, wherein in the step (3), the granulating agent is a mixture of fatty acid monoglyceride and phospholipid in a mass ratio of 1.2-1.5: 1.
4. The method for preparing NMN capsules according to claim 3, wherein said monoglyceride of fatty acids is selected from the group consisting of glyceryl monostearate, glyceryl monolaurate and glyceryl monooleate.
5. The method for preparing NMN capsules according to claim 3, wherein said phospholipids are selected from the group consisting of egg yolk lecithin, soybean phospholipids, and sunflower phospholipids.
6. The method for preparing NMN capsules according to any one of claims 2 to 5, wherein in step (3), the mass ratio of NMN, granulating agent and water is 3.5-5: 1.5-2: 4 to 7.5.
CN202110856282.5A 2021-07-28 2021-07-28 NMN capsule coating and NMN capsule preparation method and application Active CN113633626B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110856282.5A CN113633626B (en) 2021-07-28 2021-07-28 NMN capsule coating and NMN capsule preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110856282.5A CN113633626B (en) 2021-07-28 2021-07-28 NMN capsule coating and NMN capsule preparation method and application

Publications (2)

Publication Number Publication Date
CN113633626A CN113633626A (en) 2021-11-12
CN113633626B true CN113633626B (en) 2022-09-27

Family

ID=78418611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110856282.5A Active CN113633626B (en) 2021-07-28 2021-07-28 NMN capsule coating and NMN capsule preparation method and application

Country Status (1)

Country Link
CN (1) CN113633626B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104758307A (en) * 2015-03-16 2015-07-08 邦泰生物工程(深圳)有限公司 Application of NADH and NMN in preparation of drug or health caring product for Parkinson's disease
CN110237089A (en) * 2019-06-19 2019-09-17 泓博元生命科技（深圳）有限公司 The application of NADH and/or NMN prevention and treatment male erectile dysfunction
CN112386581A (en) * 2020-09-24 2021-02-23 赫曼因生物科技有限公司 Coating formula of acid-resistant enteric NMN capsule
CN112641761A (en) * 2020-12-28 2021-04-13 厦门金达威生物科技有限公司 Stable NMN sustained-release pellet and preparation method and application thereof
CN112972426A (en) * 2021-02-23 2021-06-18 成都西域从容生物科技有限公司 NMN-containing capsule and preparation method thereof

Also Published As

Publication number Publication date
CN113633626A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
CN106727441B (en) Water-soluble nano slow-release functional coenzyme Q10 microcapsule and preparation method and application thereof
JP5198858B2 (en) Carrier for enteral administration
Amal El Sayeh et al. Ketorolac tromethamine floating beads for oral application: characterization and in vitro/in vivo evaluation
WO2010081259A1 (en) A composition comprising extraction of fucoxanthin
CN105476020A (en) Vitamin D3 soft capsule and preparation method thereof
CN103919715A (en) Controlled Release Drug Combination Containing Choline Alfoscerate Or Salt Thereof And Method For Preparing Same
IE61999B1 (en) Pharmaceutical dosage form for the medication of fish
CN108926534B (en) Modified KGM lecithin NMN-loaded transdermal ethosome, preparation process and application thereof
CN103349666A (en) Pharmaceutical composition injection of compound liposoluble vitamin and preparation method thereof
CN113559112B (en) Preparation method and application of NMN-containing composition
CN113633626B (en) NMN capsule coating and NMN capsule preparation method and application
CN108938601B (en) Metformin hydrochloride enteric-coated sustained-release pellet and preparation method thereof
CN107349238A (en) A kind of auxiliary improvement of memory acer truncatum seed oil compound preparation and its application
CN106723064B (en) Vitamin D3Soft capsule and preparation method thereof
CN102716135B (en) Lupenone prevents in preparation or treats the application in the product of diabetes
CN102010512B (en) Preparation method and application of water-soluble chitosan micro-particles
CN105748489A (en) A composite vitamin ADE oil injection for veterinary use and a preparing method thereof
CN115444893B (en) Uric acid reducing active substance composition and application thereof
CN105963254A (en) Coenzyme Q10 pharmaceutical composition and preparation process thereof
CN101933913A (en) Dexmethylphenidate hydrochloride dual-release preparation and preparation method thereof
CN104288107B (en) Sustained-release floating micropill, pharmaceutical composition containing the pellet and preparation method thereof
CN114983938A (en) Orlistat oral composite emulsion and preparation method thereof
CN104288106B (en) Sustained-release floating micropill, pharmaceutical composition containing the micropill and preparation method thereof
CN106309410B (en) A kind of monosialotetrahexose ganglioside sodium spansule and preparation method thereof
CN102626411A (en) Pharmaceutical composition containing propofol and opioid analgesics and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant